Tocilizumab and the risk for cardiovascular disease: A direct comparison among biologic disease‐modifying antirheumatic drugs for rheumatoid arthritis patients
Xie F et al. Arthritis Care Res 2018. doi: 10.1002/acr.23737
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.